Aptus Pharma was originally incorporated as ‘Aptus Pharma Private Limited’, as a private limited company under the Companies Act, 1956, with the Registrar of Companies (ROC), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of the company was changed to ‘Aptus Pharma Limited’ and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre.

It is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It does not own any manufacturing plants but has entered into contract manufacturing agreement with several manufacturing units, under various arrangements. Of these, it has formal loan and license agreements in place with few manufacturing units. The remaining production is carried out through informal arrangements with other manufacturers, based on purchase orders (PO). It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.

Its manufacturing partners are selected based on stringent quality, compliance, and delivery standards. These manufacturers are required to hold WHO-GMP, Certifications, and are subject to periodic review and audits by its quality assurance team. Before placing purchase orders with its contract manufacturers, it ensures about their certifications, clientele, manufacturing infrastructure, and their delivery capabilities through proper due diligence and proper documentation with regards to defined terms for quality control parameters, packaging standards, lead times, and logistics.

Its quality assurance framework includes real-time lab analysis of every batch during and after manufacturing, with testing conducted at affiliated certified laboratories. It follows established quality control protocols, including compound assay, disintegration, dissolution, stability, friability, uniform drug distribution, and content uniformity tests. 

Business area of the company

The company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc.

Product categories of the company

• Anti-infectives
• Antacids & PPI
• G.I. medicines
• Anti-allergic and respiratory medicine
• Nutritional supplements 
• Anti-inflammatory and pain management
• Neuro-psychiatric medicine
• lipid lowering medicine
• anti-hypertensive & cardiovascular medicine
• Antidiabetic medicine
• Consumer care

Awards and accreditation

• 2017: Best Company in Quality Control 2017 - India 5000 MSME
• 2019: Best Company in Quality Control Indian Pharma Expo 2019
• 2020: Chilkul Most Trusted Brand of Region - CIMS Publication & IDR
• 2021: Business Excellence Pharma & Healthcare - Zee 24
• 2021: Best Healthcare Brand ‘Chilkul’ - BHB Economic Times 2021
• 2022: Business excellence award emerging pharma company of Gujarat (IDR CIMS MEDICA 2022)
• 2023: Promising Entrepreneur of India - Economic Times
• 2023: Best Healthcare Brand ‘Chilkul’ - BHB Economic Times 2023

History and milestones

• 2010: Incorporation of the company under the name ‘Aptus Pharma Private Limited’ 
• 2011-2013: Commenced operations through four regional headquarters in Gujarat. Launched a portfolio of 25 products targeting essential therapeutic segments. 
• 2013-2016: Achieved around 33% geographical coverage in Gujarat. Expanded product portfolio to over 50 products, catering to both acute and chronic segments. 
• 2016-2019: Increased portfolio to over 70 products in response to evolving therapeutic requirements. 
• 2019-2022: Extended presence to around 80% of Gujarat, including remote areas. Product portfolio grew to over 100 products. Appointed a C&F agent in Ahmedabad and improved logistics infrastructure. 
• 2022-2024: Achieved full geographical coverage across Gujarat. Expanded product portfolio to over 175 products. Established three operational divisions: Acute, Chronic, and OTC. Initiated in-house manufacturing under a loan license arrangement. 
• 2024: Converted to a public limited company and changed name to ‘Aptus Pharma Limited’.